Salcaprozate-based ionic liquids for GLP-1 gastric delivery: A mechanistic understanding of in vivo performance.

RPEP-13225Preclinicallow2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
preclinical
Evidence
low
Sample
N=Not specified (preclinical animal studies)
Participants
Rats and dogs (preclinical pharmacokinetic models)

What This Study Found

A salcaprozate-based ionic liquid formulation delivered a GLP-1 analogue faster through the stomach lining than standard tablets in rats and anesthetized dogs, but showed lower overall absorption in awake dogs due to gastric fluid dilution and rapid emptying.

Key Numbers

Peptide loading and release rates characterized in vitro. Storage stable for 3 weeks at 4 degrees C. Faster absorption onset vs. tablet in rats and anesthetized dogs. Lower overall exposure in awake dogs.

How They Did This

In vitro characterization of ionic liquid formulation. In vivo pharmacokinetic studies in rats, anesthetized dogs, and awake dogs. Compared to tablet reference formulation.

Why This Research Matters

Oral peptide drugs like semaglutide require patients to fast and wait before eating. A liquid formulation that works faster could be more convenient, but keeping the drug in contact with the stomach lining long enough remains a challenge.

What This Study Doesn't Tell Us

Animal studies only. Awake dog results showed inferior overall absorption. Gastric physiology (fluid dilution, rapid liquid transit) poses major hurdles. Single GLP-1 analogue tested. No human data.

Trust & Context

Original Title:
Salcaprozate-based ionic liquids for GLP-1 gastric delivery: A mechanistic understanding of in vivo performance.
Published In:
Journal of controlled release : official journal of the Controlled Release Society, 377, 267-276 (2025)
Database ID:
RPEP-13225

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-13225·https://rethinkpeptides.com/research/RPEP-13225

APA

Rebollo, René; Niu, Zhigao; Blaabjerg, Lasse; La Zara, Damiano; Juel, Trine; Pedersen, Henrik Duelund; Andersson, Vincent; Benova, Michaela; Krogh, Camilla; Pons, Raphaël; Holm, Tobias Palle; Wahlund, Per-Olof; Fan, Li; Wang, Zhuoran; Kennedy, Adam; Kuhre, Rune Ehrenreich; Christophersen, Philip; Bardonnet, Pierre-Louis; Sassene, Philip Jonas. (2025). Salcaprozate-based ionic liquids for GLP-1 gastric delivery: A mechanistic understanding of in vivo performance.. Journal of controlled release : official journal of the Controlled Release Society, 377, 267-276. https://doi.org/10.1016/j.jconrel.2024.11.036

MLA

Rebollo, René, et al. "Salcaprozate-based ionic liquids for GLP-1 gastric delivery: A mechanistic understanding of in vivo performance.." Journal of controlled release : official journal of the Controlled Release Society, 2025. https://doi.org/10.1016/j.jconrel.2024.11.036

RethinkPeptides

RethinkPeptides Research Database. "Salcaprozate-based ionic liquids for GLP-1 gastric delivery:..." RPEP-13225. Retrieved from https://rethinkpeptides.com/research/rebollo-2025-salcaprozatebased-ionic-liquids-for

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.